PT2503995T - Métodos de liofilização, composições e kits - Google Patents

Métodos de liofilização, composições e kits

Info

Publication number
PT2503995T
PT2503995T PT108338625T PT10833862T PT2503995T PT 2503995 T PT2503995 T PT 2503995T PT 108338625 T PT108338625 T PT 108338625T PT 10833862 T PT10833862 T PT 10833862T PT 2503995 T PT2503995 T PT 2503995T
Authority
PT
Portugal
Prior art keywords
kits
compositions
lyophilization methods
lyophilization
methods
Prior art date
Application number
PT108338625T
Other languages
English (en)
Inventor
Guo Jianxin
Klos Anthony
Barnette Deborah
Original Assignee
Grifols Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44067198&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2503995(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grifols Therapeutics Inc filed Critical Grifols Therapeutics Inc
Publication of PT2503995T publication Critical patent/PT2503995T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Drying Of Solid Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT108338625T 2009-11-24 2010-11-23 Métodos de liofilização, composições e kits PT2503995T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26401409P 2009-11-24 2009-11-24

Publications (1)

Publication Number Publication Date
PT2503995T true PT2503995T (pt) 2017-11-23

Family

ID=44067198

Family Applications (1)

Application Number Title Priority Date Filing Date
PT108338625T PT2503995T (pt) 2009-11-24 2010-11-23 Métodos de liofilização, composições e kits

Country Status (19)

Country Link
US (1) US8648177B2 (pt)
EP (1) EP2503995B1 (pt)
JP (2) JP5810091B2 (pt)
KR (1) KR101567901B1 (pt)
CN (1) CN102762196B (pt)
AU (1) AU2010324839B2 (pt)
BR (1) BR112012012460B1 (pt)
CA (1) CA2781120C (pt)
CL (1) CL2012001350A1 (pt)
ES (1) ES2648249T3 (pt)
HU (1) HUE037733T2 (pt)
IL (1) IL219827A (pt)
MX (1) MX2012005782A (pt)
NZ (1) NZ600271A (pt)
PL (1) PL2503995T3 (pt)
PT (1) PT2503995T (pt)
RU (1) RU2540480C2 (pt)
WO (1) WO2011066291A2 (pt)
ZA (1) ZA201203603B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2679819T3 (es) 2009-11-03 2018-08-31 Grifols Therapeutics Inc. Composición, método y kit para inhibidor de alfa-1 proteinasa
AU2010324839B2 (en) 2009-11-24 2015-02-19 Grifols Therapeutics Inc. Lyophilization methods, compositions, and kits
US10227289B2 (en) 2010-05-07 2019-03-12 Medicus Biosciences, Llc Methods for treating diseases of the lung
US11083821B2 (en) 2011-08-10 2021-08-10 C.P. Medical Corporation Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules
US10111985B2 (en) 2011-08-10 2018-10-30 Medicus Biosciences, Llc Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules
CN104428014B (zh) 2012-05-11 2016-11-09 梅迪卡斯生物科学有限责任公司 针对视网膜脱离的生物相容性水凝胶治疗
MX363511B (es) 2012-08-16 2019-03-26 Pfizer Proceso de glucoconjugación y composiciones.
US20140199286A1 (en) * 2013-01-15 2014-07-17 Teva Pharmaceutical Industries, Ltd. Lyophilization process
JP6525952B2 (ja) * 2013-03-14 2019-06-05 メディカス バイオサイエンシーズ エルエルシー 細胞送達のための生体適合性ヒドロゲルポリマーマトリックス
US10004043B2 (en) 2013-06-18 2018-06-19 Lg Electronics Inc. Method for controlling electric power in wireless communication system supporting change in purpose of wireless resource and apparatus therefor
PL3065756T3 (pl) * 2013-11-07 2019-07-31 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Stabilnie przechowywane liofilizowane formulacje tripeptydowe
US10584371B2 (en) * 2015-02-13 2020-03-10 Seegene, Inc. Method for lyophilization of composition for multiple target nucleic acid sequence amplification reaction
CN104856965B (zh) * 2015-05-29 2018-07-20 湖南科伦制药有限公司 一种注射用胸腺肽的冻干方法
RU2018112431A (ru) 2015-09-07 2019-10-09 Мотида Фармасьютикал Ко., Лтд. Лиофилизированный препарат альгиновой кислоты
TW201715185A (zh) * 2015-10-29 2017-05-01 Tai Yiaeh Enterprise Co Ltd 冷凍過程的即時檢測方法
CN107467013A (zh) * 2017-09-20 2017-12-15 上海贞元诊断用品科技有限公司 一种可长期保存的质控品通用血浆基质制备方法
CN107677528A (zh) * 2017-09-20 2018-02-09 上海贞元诊断用品科技有限公司 一种肝素抗凝检测试剂的校准品及质控品及其制备方法
JP7110360B2 (ja) 2017-10-09 2022-08-01 テルモ ビーシーティー バイオテクノロジーズ，エルエルシー 凍結乾燥方法
JP7471316B2 (ja) 2019-03-14 2024-04-19 テルモ ビーシーティー バイオテクノロジーズ，エルエルシー マルチパート凍結乾燥容器
WO2024150915A1 (ko) * 2023-01-11 2024-07-18 주식회사 풀바이오스 미세먼지로 인한 피부 손상 보호 및 탈모 방지용 조성물 및 그 제조방법

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087415A (en) * 1976-06-09 1978-05-02 William L. Wilson Antithrombin III
JPS597693B2 (ja) * 1978-01-07 1984-02-20 株式会社ミドリ十字 抗トロンビン製剤及びその製法
US4337242A (en) 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
DE3262575D1 (en) 1981-12-23 1985-04-18 Schering Corp Stabilised interferon formulations and their preparation
US4517294A (en) 1982-03-03 1985-05-14 Genentech, Inc. Human antithrombin III
US4632981A (en) 1982-07-30 1986-12-30 Genentech, Inc. Human antithrombin III
US5218091A (en) 1982-08-13 1993-06-08 Zymogenetics, Inc. Glycolytic promoters for regulated protein expression: protease inhibitor
US4711848A (en) 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4732973A (en) 1984-06-14 1988-03-22 Chiron Corporation Active site modified protease α-1-antitrypsin inhibitors
JP2599585B2 (ja) 1984-06-19 1997-04-09 トランスジ−ン ソシエテ アノニム ヒトα▲下１▼−アンチトリプシン誘導体及びその製造法
US5322775A (en) 1986-06-30 1994-06-21 Pharmaceutical Proteins Ltd. Peptide production
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
DE3901917A1 (de) 1989-01-24 1990-07-26 Behringwerke Ag Mutanten von humanem antithrombin iii
GB8913183D0 (en) 1989-06-08 1989-07-26 Central Blood Lab Authority Chemical products
US5079336A (en) 1989-06-23 1992-01-07 The Trustees Of The University Of Pennsylvania α-1-antichymotrypsin, analogues and methods of production
US5032405A (en) 1989-09-27 1991-07-16 Warner-Lambert Company Oral pharmaceutical composition for acid sensitive proteinaceous agents
US5134119A (en) 1990-10-16 1992-07-28 Lezdey John Treatment of inflammation using 358 substituted alpha-antitrypsin
JP3479539B2 (ja) 1992-04-10 2003-12-15 エーザイ株式会社 ヒトアンチトロンビンｉｉｉ変異体
US5561115A (en) 1994-08-10 1996-10-01 Bayer Corporation Low temperature albumin fractionation using sodium caprylate as a partitioning agent
US5843705A (en) 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
AT405905B (de) * 1997-03-25 1999-12-27 Immuno Ag Neue verwendung von antithrombin iii
AT407114B (de) 1997-06-10 2000-12-27 Immuno Ag Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung
CA2328397A1 (en) 1998-05-12 1999-11-18 Temple University - Of The Commonwealth System Of Higher Education Human antithrombin iiis and methods related thereto
DK2130554T3 (da) * 1999-02-22 2012-12-03 Univ Connecticut Albuminfrie faktor VIII-præparater
US20040157911A1 (en) 1999-08-31 2004-08-12 Spiridon Spireas Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof
EP1298217A4 (en) 2000-07-05 2004-09-08 Mitsubishi Pharma Corp GLYCOPROTEIN PRODUCTION PROCESS
US6432658B1 (en) * 2000-09-13 2002-08-13 Affinity Biologicals, Inc. Method for measuring antithrombin activity
US20050013867A1 (en) 2001-10-19 2005-01-20 Lehrman S. Russ Use of proton sequestering agents in drug formulations
WO2003086451A1 (en) 2002-04-05 2003-10-23 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
IL164795A0 (en) 2002-04-25 2005-12-18 Scripps Research Inst Treatment and prevention of pulmonary conditions
WO2005027821A2 (en) 2003-09-22 2005-03-31 Kamada Ltd. Large scale preparation of alpha-1 proteinase inhibitor and use thereof
US7691810B2 (en) 2003-10-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Method of producing recombinant antithrombin III composition
ATE530165T1 (de) 2003-11-14 2011-11-15 Baxter Int Alpha1-antitrypsin-zusammensetzungen und behandlungsverfahren unter verwendung dieser zusammensetzungen
US20050226893A1 (en) 2004-03-04 2005-10-13 Jennifer Juneau Lyophilization method to improve excipient crystallization
JP2009516692A (ja) * 2005-11-22 2009-04-23 ワイス 免疫グロブリン融合タンパク質製剤
EP2740487B1 (en) 2006-02-09 2018-02-28 Kamada Ltd. Alpha-i antitrypsin for treating exacerbation episodes of pulmonary diseases
JP2010506129A (ja) * 2006-10-03 2010-02-25 ワイス エルエルシー 凍結乾燥法および装置
AU2010324839B2 (en) * 2009-11-24 2015-02-19 Grifols Therapeutics Inc. Lyophilization methods, compositions, and kits

Also Published As

Publication number Publication date
CN102762196B (zh) 2014-05-14
ZA201203603B (en) 2016-01-27
AU2010324839A1 (en) 2012-06-14
JP2015155455A (ja) 2015-08-27
CA2781120A1 (en) 2011-06-03
CL2012001350A1 (es) 2012-09-28
BR112012012460B1 (pt) 2020-06-23
JP2013512194A (ja) 2013-04-11
HUE037733T2 (hu) 2018-09-28
EP2503995A2 (en) 2012-10-03
IL219827A0 (en) 2012-07-31
CA2781120C (en) 2015-01-27
BR112012012460A2 (pt) 2017-10-10
EP2503995A4 (en) 2014-05-21
KR101567901B1 (ko) 2015-11-10
WO2011066291A4 (en) 2011-12-22
US8648177B2 (en) 2014-02-11
KR20120102715A (ko) 2012-09-18
IL219827A (en) 2016-12-29
AU2010324839B2 (en) 2015-02-19
CN102762196A (zh) 2012-10-31
ES2648249T3 (es) 2017-12-29
WO2011066291A3 (en) 2011-10-06
RU2012126125A (ru) 2013-12-27
RU2540480C2 (ru) 2015-02-10
JP5810091B2 (ja) 2015-11-11
BR112012012460A8 (pt) 2018-07-03
US20130040890A1 (en) 2013-02-14
EP2503995B1 (en) 2017-11-01
MX2012005782A (es) 2012-08-03
NZ600271A (en) 2013-09-27
PL2503995T3 (pl) 2018-01-31
WO2011066291A2 (en) 2011-06-03

Similar Documents

Publication Publication Date Title
ZA201203603B (en) Lyophilization methods, compositions, and kits
IL210153A0 (en) Nutrigenomics methods and compositions
IL212822A0 (en) Anti-cxcr1 compositions and methods
GB0819530D0 (en) Methods and compositions
IL210559A0 (en) Novel compositions and methods
IL210588A0 (en) Novel compositions and methods
GB0903299D0 (en) Composition and methods
GB0817585D0 (en) Novel compositions and methods
EP2438173A4 (en) BIOMATERIALS, COMPOSITIONS AND METHODS
HK1149770A1 (en) Compositions, methods and kits
GB0901494D0 (en) Compositions and Methods
HRP20150021T1 (en) Phenanthrenone compounds, compositions and methods
GB0811250D0 (en) Methods and compositions
GB0912287D0 (en) Cells, compositions and methods
GB0913162D0 (en) Compositions and kits
GB0901227D0 (en) Composition,method and use
GB0901293D0 (en) Composition, method and use
GB0901234D0 (en) Composition,method and use
GB0818399D0 (en) Methods and compositions
GB0816534D0 (en) Compositions and methods
GB0811152D0 (en) Methods and compositions
GB0803464D0 (en) Methods and compositions